Rajath Govind
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Rajath Govind has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Amul Kapoor
Department of Medical Oncology, Army Hospital (R&R), New Delhi, India
1 shared publicationArti Sarin
Director General Armed Forces Medical Services, New Delhi, India
1 shared publication- Kaushik M. R.
Department of Medical Oncology, INHS ASVINI, Mumbai, Maharashtra, India
1 shared publication - Naveen Kumar Kushwaha
Department of Thoracic Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
1 shared publication - Nihanthy D. Sreenath
Department of Medical Oncology, Saroj Gupta Cancer Centre and Research Institute, Kolkata, West Bengal, India
1 shared publication - Niharika Bisht
Department of Radiation Oncology, Army Hospital (R&R), New Delhi, India
1 shared publication
Latest Publications
- Open Access
- 18 March 2026
- Published by Georg Thieme Verlag KG in Indian Journal of Medical and Paediatric Oncology
The Contribution of Nontherapeutic Expenses Toward Financial Toxicity in Free Health Care Setting: A Cross-Sectional Survey in a Tertiary Care Hospital in India
The financial burden caused by the long-term treatment of cancer is a harsh reality in low- to middle-income countries due to the vicious cycle of poverty, lack of health insurance, and illiteracy. In addition to the cost of diagnostic tests and therapy, it also includes the money spent on travel to and living in a new city owing to the lack of health care facilities near one's own residence. Several studies have highlighted the impact of this financial strain; however, studies evaluating its effect in background of free health care are lacking. We sought to estimate “financial toxicity” and its contributing factors in a specific population with access to free health care. This cross-sectional survey was conducted at the oncology center of a tertiary care hospital in India. The survey consisted of (1) demographic, cancer, and therapy-related details; (2) the COST-FACIT (Comprehensive Score for Financial Toxicity–Functional Assessment of Chronic Illness Therapy) questionnaire determining the financial toxicity score; and (3) an additional questionnaire with information about expenditure breakup, present financial condition, and quantification of monetary impact on the family. A total of 300 patients who had received or were currently on treatment completed the survey. All patients in our study were immediate family members of government employees (current or retired). As a fully government-funded hospital, all patients at our institute were eligible to receive free treatment, inpatient management, and medication. Of the respondents, 61.3% were female. The average treatment duration in our survey was 8.03 months, with a mean patient age of 43.14 years. The most common causes of expenditure were travel, accommodation, and food-related expenses (75.7%). This finding was despite the availability of subsidized facilities. In addition, 34.5% spent money on unanticipated therapy-related costs (additional diagnostic tests, drugs unavailable in the hospital, or alternate therapies). The mean COST-FACIT score was 21.38 (range: 20–24), indicating mild financial toxicity. Predictors of high financial toxicity were rural residence, older age, and higher additional expenses after cancer diagnosis. Financial toxicity is a problem faced by almost all oncology patients, even with the availability of free health care. Although financial toxicity was measured as mild, a significant number of families had to dip into their savings or sell assets to support their treatment.
- 18 March 2026
- Published by Georg Thieme Verlag KG in Indian Journal of Medical and Paediatric Oncology
Open AccessThe Contribution of Nontherapeutic Expenses Toward Financial Toxicity in Free Health Care Setting: A Cross-Sectional Survey in a Tertiary Care Hospital in India
The financial burden caused by the long-term treatment of cancer is a harsh reality in low- to middle-income countries due to the vicious cycle of poverty, lack of health insurance, and illiteracy. In addition to the cost of diagnostic tests and therapy, it also includes the money spent on travel to and living in a new city owing to the lack of health care facilities near one's own residence. Several studies have highlighted the impact of this financial strain; however, studies evaluating its effect in background of free health care are lacking. We sought to estimate “financial toxicity” and its contributing factors in a specific population with access to free health care. This cross-sectional survey was conducted at the oncology center of a tertiary care hospital in India. The survey consisted of (1) demographic, cancer, and therapy-related details; (2) the COST-FACIT (Comprehensive Score for Financial Toxicity–Functional Assessment of Chronic Illness Therapy) questionnaire determining the financial toxicity score; and (3) an additional questionnaire with information about expenditure breakup, present financial condition, and quantification of monetary impact on the family. A total of 300 patients who had received or were currently on treatment completed the survey. All patients in our study were immediate family members of government employees (current or retired). As a fully government-funded hospital, all patients at our institute were eligible to receive free treatment, inpatient management, and medication. Of the respondents, 61.3% were female. The average treatment duration in our survey was 8.03 months, with a mean patient age of 43.14 years. The most common causes of expenditure were travel, accommodation, and food-related expenses (75.7%). This finding was despite the availability of subsidized facilities. In addition, 34.5% spent money on unanticipated therapy-related costs (additional diagnostic tests, drugs unavailable in the hospital, or alternate therapies). The mean COST-FACIT score was 21.38 (range: 20–24), indicating mild financial toxicity. Predictors of high financial toxicity were rural residence, older age, and higher additional expenses after cancer diagnosis. Financial toxicity is a problem faced by almost all oncology patients, even with the availability of free health care. Although financial toxicity was measured as mild, a significant number of families had to dip into their savings or sell assets to support their treatment.
- Open Access
- 20 February 2025
- Published by Georg Thieme Verlag KG in Indian Journal of Medical and Paediatric Oncology
Optimizing Oncological Care in Patients with End-Stage Chronic Kidney Disease on Dialysis: Indian Scenario
Background In India, around 55,000 patients are on dialysis, with a 10–20% annual increase. With the growing dialysis population in India, cancer risk among end-stage renal disease (ESRD) patients is increasing. Managing chemotherapy in these patients is challenging due to limited data and guidelines, leading to treatment uncertainty. Objectives This study provides real-world data from India on the clinical management and outcomes of cancer patients with ESRD undergoing dialysis while receiving chemotherapy. Material and Methods This prospective study analyzed data from five cancer patients with end-stage renal disease (ESRD) on hemodialysis prior to diagnosis of cancer treated at a tertiary oncology center in India. We analyzed the demographic details, cancer staging, treatment regimens, and dosage adjustments. Treatment modifications due to renal dysfunction, toxicities, and patient outcomes were also reviewed over a 12-month follow-up. Results The cohort consisted of 80% (4/5 pts) females, with a median age of 57.8 years. Hypertensive and diabetic nephropathy were the leading causes of ESRD. Cancers included breast (3/5 pts), lung (1/5 pts), and ovarian (1/5 pts), with varying stages of diagnosis. 80% (4/5) of patients required tailored drug management. The Ovarian cancer patient experienced severe hypersensitivity to carboplatin, which was managed conservatively. No grade 3/4 immune-related adverse events occurred, and all patients were alive and disease-free at the one-year follow-up. Conclusion Carefully tailored treatment strategies and a coordinated multidisciplinary approach allowed positive outcomes for cancer patients on dialysis, emphasizing the need for personalized approaches. These findings highlight the importance of refining treatment protocols for this complex group.
- 20 February 2025
- Published by Georg Thieme Verlag KG in Indian Journal of Medical and Paediatric Oncology
Open AccessOptimizing Oncological Care in Patients with End-Stage Chronic Kidney Disease on Dialysis: Indian Scenario
Background In India, around 55,000 patients are on dialysis, with a 10–20% annual increase. With the growing dialysis population in India, cancer risk among end-stage renal disease (ESRD) patients is increasing. Managing chemotherapy in these patients is challenging due to limited data and guidelines, leading to treatment uncertainty. Objectives This study provides real-world data from India on the clinical management and outcomes of cancer patients with ESRD undergoing dialysis while receiving chemotherapy. Material and Methods This prospective study analyzed data from five cancer patients with end-stage renal disease (ESRD) on hemodialysis prior to diagnosis of cancer treated at a tertiary oncology center in India. We analyzed the demographic details, cancer staging, treatment regimens, and dosage adjustments. Treatment modifications due to renal dysfunction, toxicities, and patient outcomes were also reviewed over a 12-month follow-up. Results The cohort consisted of 80% (4/5 pts) females, with a median age of 57.8 years. Hypertensive and diabetic nephropathy were the leading causes of ESRD. Cancers included breast (3/5 pts), lung (1/5 pts), and ovarian (1/5 pts), with varying stages of diagnosis. 80% (4/5) of patients required tailored drug management. The Ovarian cancer patient experienced severe hypersensitivity to carboplatin, which was managed conservatively. No grade 3/4 immune-related adverse events occurred, and all patients were alive and disease-free at the one-year follow-up. Conclusion Carefully tailored treatment strategies and a coordinated multidisciplinary approach allowed positive outcomes for cancer patients on dialysis, emphasizing the need for personalized approaches. These findings highlight the importance of refining treatment protocols for this complex group.